Illumina (NASDAQ:ILMN) Director Keith Meister Sells 138,379 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 138,379 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the transaction, the director owned 1,033,910 shares in the company, valued at $236,651,659.90. This represents a 11.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Illumina Stock Up 1.3%

Shares of ILMN stock traded up $2.85 on Thursday, reaching $227.69. 1,937,136 shares of the company were exchanged, compared to its average volume of 2,109,322. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a 50-day moving average of $192.98 and a 200-day moving average of $155.18. The company has a market cap of $34.38 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 3.16 and a beta of 1.45. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ILMN. Citigroup lifted their price target on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd. TD Cowen raised their price objective on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Stifel Nicolaus lifted their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Finally, Royal Bank Of Canada upped their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $188.40.

Hedge Funds Weigh In On Illumina

Several large investors have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its holdings in Illumina by 16,869.5% during the second quarter. California State Teachers Retirement System now owns 40,144,099 shares of the life sciences company’s stock worth $7,058,537,000 after purchasing an additional 39,907,533 shares during the last quarter. BlackRock Inc. purchased a new stake in Illumina in the 2nd quarter valued at about $3,374,423,000. Primecap Management Co. CA bought a new position in shares of Illumina during the 2nd quarter worth approximately $617,981,000. Jupiter Topco LLC purchased a new position in shares of Illumina in the 2nd quarter worth approximately $358,652,000. Finally, WCM Investment Management LLC boosted its stake in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.